Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,621
archived clinical trials in
Urology

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
659
mi
from
Jeffersonville, IN
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
659
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
573
mi
from
Newburg, IN
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
573
mi
from
Newburg, IN
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
434
mi
from
Shreveport, LA
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
434
mi
from
Shreveport, LA
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
1155
mi
from
Annapolis, MD
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
1155
mi
from
Annapolis, MD
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
475
mi
from
Southaven, MS
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
475
mi
from
Southaven, MS
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
1035
mi
from
Missoula, MT
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
1035
mi
from
Missoula, MT
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
1248
mi
from
Lawrence, NJ
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
1248
mi
from
Lawrence, NJ
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
517
mi
from
Albuquerque, NM
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
517
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
1287
mi
from
Brooklyn, NY
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
1287
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
969
mi
from
Concord, NC
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
969
mi
from
Concord, NC
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
645
mi
from
Bismarck, ND
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
645
mi
from
Bismarck, ND
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
1163
mi
from
Lancaster, PA
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
1163
mi
from
Lancaster, PA
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
779
mi
from
Knoxville, TN
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
779
mi
from
Knoxville, TN
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
353
mi
from
Arlington, TX
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
353
mi
from
Arlington, TX
Click here to add this to my saved trials
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated:  7/2/2012
Clinical Research Facility
571
mi
from
San Antonio, TX
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart
Status: Enrolling
Updated: 7/2/2012
Clinical Research Facility
571
mi
from
San Antonio, TX
Click here to add this to my saved trials
Prospective Pediatric Vesicoureteral Reflux Surgery Database
Prospective Pediatric Vesicoureteral Reflux Surgery Database
Status: Enrolling
Updated:  7/3/2012
Connecticut Children's Medical Center
1358
mi
from
Hartford, CT
Prospective Pediatric Vesicoureteral Reflux Surgery Database
Prospective Pediatric Vesicoureteral Reflux Surgery Database
Status: Enrolling
Updated: 7/3/2012
Connecticut Children's Medical Center
1358
mi
from
Hartford, CT
Click here to add this to my saved trials
Renal Retention of Microbubbles
Study of Whether There is Renal Retention of Lipid Microbubble Ultrasound Contrast Agents
Status: Enrolling
Updated:  7/20/2012
Oregon Health and Science University
1383
mi
from
Portland, OR
Renal Retention of Microbubbles
Study of Whether There is Renal Retention of Lipid Microbubble Ultrasound Contrast Agents
Status: Enrolling
Updated: 7/20/2012
Oregon Health and Science University
1383
mi
from
Portland, OR
Click here to add this to my saved trials
Lessening Incontinence by Learning Yoga
Status: Enrolling
Updated:  8/21/2012
University of California, San Francisco
1339
mi
from
San Francisco, CA
Lessening Incontinence by Learning Yoga
Status: Enrolling
Updated: 8/21/2012
University of California, San Francisco
1339
mi
from
San Francisco, CA
Click here to add this to my saved trials
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)
Open-Label, Six-Month Extension of Protocol MCS-2-TWN-a to Further Evaluate the Efficacy and Safety of MCS-2 for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects
Status: Enrolling
Updated:  9/7/2012
David Geffen School of Medicine, UCLA
1177
mi
from
Los Angeles, CA
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)
Open-Label, Six-Month Extension of Protocol MCS-2-TWN-a to Further Evaluate the Efficacy and Safety of MCS-2 for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Treatment Naïve Male Subjects
Status: Enrolling
Updated: 9/7/2012
David Geffen School of Medicine, UCLA
1177
mi
from
Los Angeles, CA
Click here to add this to my saved trials
MCS in the Treatment of Lower Urinary Tract Symptoms
An Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Study to Establish the Dosage, Efficacy, and Safety of MCS-2 in Treating Lower Urinary Tract Symptoms Suggestive of BPH in Treatment-Naive Male Subjects
Status: Enrolling
Updated:  9/7/2012
David Geffen School of Medicine, UCLA
1177
mi
from
Los Angeles, CA
MCS in the Treatment of Lower Urinary Tract Symptoms
An Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Study to Establish the Dosage, Efficacy, and Safety of MCS-2 in Treating Lower Urinary Tract Symptoms Suggestive of BPH in Treatment-Naive Male Subjects
Status: Enrolling
Updated: 9/7/2012
David Geffen School of Medicine, UCLA
1177
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Trial for the Safety and Effectiveness of a Novel Antimicrobial-Coated Foley Catheter for Reduction of CAUTI.
A Randomized Trial for the Safety and Effectiveness of a Novel Antimicrobial-Coated Foley Catheter Attached to an Antimicrobial Anti-Reflux Device for Reduction of Catheter-Associated Urinary Tract Infection
Status: Enrolling
Updated:  9/7/2012
University of Minnesota, Fairview Medical Center
552
mi
from
Minneapolis, MN
A Trial for the Safety and Effectiveness of a Novel Antimicrobial-Coated Foley Catheter for Reduction of CAUTI.
A Randomized Trial for the Safety and Effectiveness of a Novel Antimicrobial-Coated Foley Catheter Attached to an Antimicrobial Anti-Reflux Device for Reduction of Catheter-Associated Urinary Tract Infection
Status: Enrolling
Updated: 9/7/2012
University of Minnesota, Fairview Medical Center
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children
Targeted Pathogen Replacement With Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children
Status: Enrolling
Updated:  9/27/2012
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children
Targeted Pathogen Replacement With Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children
Status: Enrolling
Updated: 9/27/2012
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
Status: Enrolling
Updated:  10/8/2012
Clinical Research Facility
1181
mi
from
Norfolk, VA
Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
Status: Enrolling
Updated: 10/8/2012
Clinical Research Facility
1181
mi
from
Norfolk, VA
Click here to add this to my saved trials
Multifaceted Treatment of Catheter-related Urinary Tract Infection
Multifaceted Treatment of Catheter-related Urinary Tract Infection
Status: Enrolling
Updated:  10/15/2012
Michael E. DeBakey VA Medical Center (152)
572
mi
from
Houston, TX
Multifaceted Treatment of Catheter-related Urinary Tract Infection
Multifaceted Treatment of Catheter-related Urinary Tract Infection
Status: Enrolling
Updated: 10/15/2012
Michael E. DeBakey VA Medical Center (152)
572
mi
from
Houston, TX
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
685
mi
from
Birmingham, AL
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
685
mi
from
Birmingham, AL
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
660
mi
from
Huntsville, AL
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
660
mi
from
Huntsville, AL
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
830
mi
from
Tucson, AZ
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
830
mi
from
Tucson, AZ
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
365
mi
from
Little Rock, AR
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
365
mi
from
Little Rock, AR
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
1157
mi
from
Anaheim, CA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
1157
mi
from
Anaheim, CA
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
411
mi
from
Denver, CO
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
411
mi
from
Denver, CO
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
1353
mi
from
New Britain, CT
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
1353
mi
from
New Britain, CT
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
1231
mi
from
Naples, FL
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
1231
mi
from
Naples, FL
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
801
mi
from
Atlanta, GA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
801
mi
from
Atlanta, GA
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
797
mi
from
Roswell, GA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
797
mi
from
Roswell, GA
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
659
mi
from
Jeffersonville, IN
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
659
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
434
mi
from
Shreveport, LA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
434
mi
from
Shreveport, LA
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
1035
mi
from
Missoula, MT
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
1035
mi
from
Missoula, MT
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
1248
mi
from
Lawrence, NJ
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
1248
mi
from
Lawrence, NJ
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
1287
mi
from
Brooklyn, NY
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
1287
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
969
mi
from
Concord, NC
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
969
mi
from
Concord, NC
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
729
mi
from
Cincinnati, OH
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
729
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
810
mi
from
Columbus, OH
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
810
mi
from
Columbus, OH
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
155
mi
from
Bethany, OK
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
155
mi
from
Bethany, OK
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
1389
mi
from
Salem, OR
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
1389
mi
from
Salem, OR
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
1221
mi
from
Bala Cynwyd, PA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
1221
mi
from
Bala Cynwyd, PA
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
1163
mi
from
Lancaster, PA
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
1163
mi
from
Lancaster, PA
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
1099
mi
from
Myrtle Beach, SC
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
1099
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
779
mi
from
Knoxville, TN
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
779
mi
from
Knoxville, TN
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
353
mi
from
Arlington, TX
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
353
mi
from
Arlington, TX
Click here to add this to my saved trials
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated:  10/31/2012
Clinical Research Facility
778
mi
from
Salt Lake City, UT
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
Phase III Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double Blind Clinical Evaluation of NX-1207 for the Treatment of BPH NX02-0017
Status: Enrolling
Updated: 10/31/2012
Clinical Research Facility
778
mi
from
Salt Lake City, UT
Click here to add this to my saved trials